476 results
Page 2 of 24
6-K
EX-99.2
qofle5j3 b4
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.2
znsb ewk8n
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
EX-99.1
d9lnnpc
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
EX-99.3
9gk87k
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.2
y8o05 ek5dw
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
1i3a9r
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.1
oglymhje
28 Jul 23
Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
9:18am
6-K
EX-99.2
c9tiomk1vd5e
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
604ff ypay8
24 Jul 23
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
12:43pm
6-K
EX-99.1
ic1zap
5 Jul 23
Current report (foreign)
8:43am
6-K
EX-99.2
vx8ek0woxg
5 Jul 23
Current report (foreign)
8:43am
6-K
EX-99.2
dhb9o
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.1
iidpagcc
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.1
n0ztuoe
11 Apr 23
Current report (foreign)
1:02pm
6-K
EX-99.1
6esu22
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
tfi2f048
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
ivqxfni7y2pzxn
21 Nov 22
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
10:05am
6-K
EX-99.2
e0eto49k5d3bb 9h1j
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
8qi44t905jrbnqkqhs
10 Nov 22
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
2:00pm
6-K
EX-99.1
tmpaz
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am